|Mr. Stanley Charles Erck||Pres, CEO & Director||649.04k||N/A||1948|
|Mr. John Joseph Trizzino||Sr. VP, Chief Bus. Officer, CFO & Treasurer||439.08k||N/A||1960|
|Mr. John A. Herrmann III||Sr. VP, Gen. Counsel & Corp. Sec.||425.02k||N/A||1966|
|Dr. Gregory M. Glenn||Pres of R&D||550.27k||N/A||1954|
|Ms. Erika S. Trahan||Sr. Mang. of Investor & PR||N/A||N/A||N/A|
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as allows immunization with much lower doses of antigen. The company also develops RSV F vaccine for older adults in Phase II clinical trial, and healthy children between two and six years of age in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus in Phase I clinical trial, as well as MERS coronavirus in animals; and combination respiratory vaccine to protect against influenza and RSV. The company has a clinical development agreement with Bill & Melinda Gates Foundation. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 7; Compensation: 8.